Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment

Lee, Leong, Campbell, Ross, Scheuermann-Freestone, Michaela, Taylor, Rachel, Gunaruwan, Prasad, Williams, Lynne, Ashrafian, Houman, Horowitz, John, Fraser, Alan G., Clarke, Kieran and Frenneaux, Michael (2005) Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation, 112 (21). pp. 3280-3288. ISSN 0009-7322

Full text not available from this repository.

Abstract

Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.

Item Type:	Article
Uncontrolled Keywords:	aged,cardiovascular agents,chronic disease,echocardiography, stress,fatty acids,female,glucose,heart failure,humans,male,middle aged,myocardial ischemia,myocardium,oxygen consumption,perhexiline,quality of life,stroke volume,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	27 Feb 2015 13:12
Last Modified:	07 Oct 2024 16:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/52305
DOI:	10.1161/CIRCULATIONAHA.105.551457

Actions (login required)

View Item